Binh Dinh Pharmaceutical and Medical Equipment JSC - Asset Resilience Ratio
Binh Dinh Pharmaceutical and Medical Equipment JSC (DBD) has an Asset Resilience Ratio of 16.71% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Binh Dinh Pharmaceutical and Medical Equipment JSC's Asset Resilience Ratio has changed over time. Check Binh Dinh Pharmaceutical and Medical Equ strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Binh Dinh Pharmaceutical and Medical Equipment JSC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Binh Dinh Pharmaceutical and Medical Equ market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₫0.00 | 0% |
| Short-term Investments | ₫449.20 Billion | 16.71% |
| Total Liquid Assets | ₫449.20 Billion | 16.71% |
Asset Resilience Insights
- Good Liquidity Position: Binh Dinh Pharmaceutical and Medical Equipment JSC maintains a healthy 16.71% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Binh Dinh Pharmaceutical and Medical Equipment JSC Industry Peers by Asset Resilience Ratio
Compare Binh Dinh Pharmaceutical and Medical Equipment JSC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for Binh Dinh Pharmaceutical and Medical Equipment JSC (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Binh Dinh Pharmaceutical and Medical Equipment JSC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.84% | ₫409.20 Billion ≈ $15.55 Million |
₫2.58 Trillion ≈ $98.18 Million |
+10.34pp |
| 2024-12-31 | 5.50% | ₫124.42 Billion ≈ $4.73 Million |
₫2.26 Trillion ≈ $86.03 Million |
-5.63pp |
| 2023-12-31 | 11.12% | ₫221.19 Billion ≈ $8.40 Million |
₫1.99 Trillion ≈ $75.57 Million |
-0.56pp |
| 2022-12-31 | 11.68% | ₫221.39 Billion ≈ $8.41 Million |
₫1.90 Trillion ≈ $72.03 Million |
+2.75pp |
| 2021-12-31 | 8.93% | ₫139.20 Billion ≈ $5.29 Million |
₫1.56 Trillion ≈ $59.25 Million |
+2.43pp |
| 2020-12-31 | 6.49% | ₫93.34 Billion ≈ $3.55 Million |
₫1.44 Trillion ≈ $54.61 Million |
-- |
About Binh Dinh Pharmaceutical and Medical Equipment JSC
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company manufactures and trades in pharmaceuticals and medical equipment in Vietnam. It offers antibiotics; anticancer drugs; hemodialysis solutions; hepatobiliary drugs; analgesic and antipyretic drugs; drugs for muscles, bones, and joints; antihistamine anti-allergy drugs; ear, eye, nose, and throat drops; cardiovascular drugs; nervous … Read more